体内
末端脱氧核苷酸转移酶
细胞凋亡
子宫肌瘤
子宫肌瘤
癌症研究
医学
生物
病理
平滑肌瘤
化学
男科
标记法
生物化学
生物技术
作者
Linlin Xu,Hiroshi Ishikawa,Yanruo Zhou,Tatsuya Kobayashi,Makio Shozu
出处
期刊:F&S science
[Elsevier]
日期:2022-01-21
卷期号:3 (2): 187-196
被引量:1
标识
DOI:10.1016/j.xfss.2022.01.005
摘要
To investigate the antitumor effects of the selective hypoxia-inducible factor-1 (HIF-1) inhibitors echinomycin and PX-478 on uterine fibroids.Experimental study using in vitro primary culture systems and an in vivo mouse xenograft model.Academic university center.Women with uterine fibroids who underwent hysterectomy or myomectomy.Administration of the selective HIF-1 inhibitors echinomycin and PX-478 to the media of the primary cultured uterine fibroid cells and to nonobese diabetic/severe combined immunodeficient mice bearing fibroid xenografts consisting of the primary cultured fibroid cells and type Ⅰ collagen gels beneath the kidney capsule.Cell proliferation was measured by Cell Counting Kit-8 assay. Apoptosis was evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay and by measuring caspase 3 and 7 activities. The xenografts were evaluated by gross appearance, surface area, and histology. The Ki-67 index was measured to evaluate proliferation of the xenografts.Both echinomycin and PX-478 inhibited cell proliferation and induced apoptosis in fibroid cells cultured under hypoxia and normoxia. Enlargement of the fibroid xenografts was significantly attenuated. The Ki-67 index significantly decreased after the administration of the HIF-1 inhibitors in the xenograft model. Eight of 27 xenografts treated with the HIF-1 inhibitors contained calcification and hyalinizing components from 3 days after the grafting to 2 weeks, suggesting that the HIF-inhibitors induce degeneration of the fibroid xenografts.The selective HIF-1 inhibitors echinomycin and PX-478 show antitumor effects against uterine fibroids both in vitro and in vivo. These findings support the potential use of HIF-1 inhibitors for the treatment of uterine fibroids.
科研通智能强力驱动
Strongly Powered by AbleSci AI